Managed Access Programs for ABL001, Asciminib

NCT04360005•Novartis Pharmaceuticals

Summary

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to ABL001, asciminib

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

•1. An independent request was received from a licensed physician.
•2. The patient has a serious or life-threatening disease or condition and there is no comparable or satisfactory alternative therapy available for diagnosis, monitoring, or treatment.

•4. There is a potential patient benefit to justify the potential risk of the treatment use, and the potential risk is not unreasonable in the context of the disease or condition to be treated.
•5. The patient must meet any other medical criteria established by the medical experts responsible for the product or by the health authority in the country of request (as applicable).
•6. Provision of the product will not interfere with the initiation, conduct, or completion of a Novartis clinical trial or overall development program.
•7. Managed Access provision is allowed per local laws/regulations

Key Dates

Last Updated

December 5, 2025

Conditions

Chronic Myeloid Leukemia in Chronic Phase

Interventions

Asciminib

DRUG

Contacts

MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs

CONTACT

Novartis Pharmaceuticals

CONTACT